3 recruiting, 1 terminated. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Myasthenia Gravis, MuSK: new trials by email Literature Review of Myasthenia Gravis, MuSK trials Research Report on Myasthenia Gravis, MuSK
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AXIS MG Patient Registry Myasthenia Gravis (MG), Myasthenia Gravis, Generalized | Recruiting | Autoimmune Neurology Alliance | 1000 | 2026-03-19 | 2026-08-17 | |
| Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis NMD670, Placebo - Myasthenia Gravis, Myasthenia Gravis, MuSK | Phase 2 | Recruiting | NMD Pharma A/S | 84 | 2024-05-16 | 2026-08-21 |
| Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) Amifampridine Phosphate - Myasthenia Gravis, MuSK, AChR Myasthenia Gravis | Phase 3 | Terminated | Catalyst Pharmaceuticals, Inc. | 63 | 2018-06-11 | 2024-05-07 |
| Myasthenia Gravis Foundation of America Global MG Patient Registry Myasthaenia Gravis, Myasthenia | Recruiting | Myasthenia Gravis Foundation of America | 3800 | 2013-10-12 | 2024-09-27 |
Myasthenia Gravis (4) · Autoimmune Diseases of the Nervous System (1) · Disease Progression (1) · Medication Adherence (1) · Neuromuscular Junction Diseases (1)
Autoimmune Diseases (4) · Immune System Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Nervous System Diseases (4) · Nervous System Neoplasms (4) · Neurodegenerative Diseases (4) · Neuromuscular Diseases (4) · Paraneoplastic Syndromes (4) · Paraneoplastic Syndromes, Nervous System (4) · Autoimmune Diseases of the Nervous System (3) · Neuromuscular Junction Diseases (3) · Behavior (1) · Disease Attributes (1) · Health Behavior (1)
Amifampridine (1)
Autoimmune Neurology Alliance (1) · Catalyst Pharmaceuticals, Inc. (1) · Myasthenia Gravis Foundation of America (1) · NMD Pharma A/S (1)
United States (4) · Italy (2) · Belgium (1) · Denmark (1) · France (1) · Georgia (1) · Netherlands (1) · Poland (1) · Serbia (1) · Spain (1)
Gary R Cutter, PhD (1) · Jared R Adams, MD, PhD (1) · Neelam Goyal, MD (1) · Renato Mantegazza, MD (1) · Richard J Nowak, MD, MS (1) · Srikanth Muppidi, MD (1)
2023 (1)